Psoriasis Drug Ilumya Launches in United States

Article

Sun Pharma announced the availability of its treatment for moderate-to-severe plaque psoriasis in the United States.

Sun Pharma announced the availability of its treatment for moderate-to-severe plaque psoriasis in the United States, according to a company press release.

Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults who are candidates for systemic therapy or phototherapy. The approval was based on data from the phase 3 reSURFACE clinical development program. Tildrakizumab-asmn is indicated at a dose of 100-mg administered as a subcutaneous injection every 12 weeks, following initial doses at weeks 0 and 4, Sun Pharma reported.

In a pooled analysis of phase 3 studies, data showed that tildrakizumab-asmn demonstrated sustained clinical benefit over a 3-year period and was well-tolerated among patients who were treated. Overall, 9 of 10 patients who achieved 75% PASI75 skin clearance at week 28 after 3 doses of tildrakizumab-asmn 100 mg mainatained their skin clearance after 3 years of treatment, according to the data. Additionally, skin clearance was sustained long-term in 67.6% of patients who had reached PASI 90 after 3 doses.

The most common adverse events include upper respiratory infections, injection site reactions, and diarrhea.

Click to continue reading on Specialty Pharmacy Times.

Related Videos
Acute psoriasis on the elbows is an autoimmune incurable dermatological skin disease. Large red, inflamed, flaky rash on the knees. Joints affected by psoriatic arthritis | Image Credit: SNAB - stock.adobe.com
Dermatologist examining the skin of a patient | Image Credit: thodonal - stock.adobe.com
Expert on Dermatology
© 2024 MJH Life Sciences

All rights reserved.